Tutogen purchase plan scuttled
This article was originally published in The Gray Sheet
Executive Summary
Tissue product manufacturer remains public after ending acquisition negotiations with an unspecified private equity firm. On Nov. 4, Tutogen Medical announced that the equity firm offered to buy the West Paterson, N.J. company for $94 mil. (1"The Gray Sheet" Nov. 10, 2003, In Brief). CEO Manfred Kruger cites "questions about the possibilities of this potential transaction closing by early 2004" as reason for the deal's demise...
You may also be interested in...
Tutogen for sale
Negotiations between Tutogen and an unnamed, "unaffiliated private equity firm" to acquire the company are expected to conclude by year-end, with due diligence to be completed by December, Tutogen says. Under a "non-binding" agreement announced Nov. 3, the equity firm has offered to purchase all outstanding Tutogen stock for $6 per share in cash - valuing the deal at about $94 mil. Tutogen has been seeking an acquirer to help grow sales of its Puros, Symmetry and PLIF specialty sterile allograft products (1"The Gray Sheet" May 5, 2003, p. 24). Zimmer, which acquired a 30% stake in Tutogen through its Centerpulse purchase earlier this year, says it is mulling the offer; however, a distribution pact with Tutogen will remain in place until expiration in 2010. Tutogen stock closed Nov. 4 at $5.59, up 23%...
Alvotech Highlights Lack Of Simponi Rivals As It Delivers Golimumab Results
Alvotech has just become the first company to announce positive topline results from a confirmatory clinical study for a proposed golimumab rival to Simponi and Simponi Aria – and moreover, the firm sees limited competition from other biosimilars on the horizon.
Xbrane Assembles The Troops As FDA Says No To Lucentis Biosimilar
Xbrane Biopharma was riding the crest of a wave with the EU launch of its biosimilar to Lucentis, following years of toil and investment. However, plans to roll out the product in the US will have to be pushed back – likely – into the middle of 2025, following a US FDA complete response letter.